Ketorolac Tromethamine ophthalmic solution recalled due to manufacturing deviations
Akorn is recalling Ketorolac Tromethamine Ophthalmic Solution nationwide due to manufacturing practice deviations. The voluntary recall affects multiple lot numbers of the 0.5% formulation.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification indicates potential for serious adverse health consequences. No illnesses or injuries have been reported, but the manufacturing deviations in this sterile ophthalmic product pose a risk to patient safety.
Plain-English summary
Akorn, Inc. is recalling Ketorolac Tromethamine Ophthalmic Solution, 0.5%, nationwide due to manufacturing practice deviations. The recall affects the drug in 3 mL, 5 mL, and 10 mL dropper bottles distributed across the United States.
The deviations from Current Good Manufacturing Practice (CGMP) standards were identified at the firm's facility in Lake Forest, Illinois. Multiple lot numbers are affected, with expiration dates ranging from October 2022 through September 2023. This is a voluntary recall initiated by the manufacturer in October 2022.
Consumers or healthcare providers who have this product should not use it. Contact your pharmacy or healthcare provider to discuss your treatment options and how to properly return or dispose of the recalled medication.
The recalled product
- Product
- Ketorolac Tromethamine Ophthalmic Solution, 0.5%, Packaged as a) 10 mL dropper bottle, NDC 17478-209-11; (b) 3 mL dropper bottle, NDC 17478-209-19; (c) 5 mL dropper bottle, NDC 17478-209-10; Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045.
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
- Hazard
- manufacturing-defect
- sterility-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: (a) 1A09A
- EXP 12/31/2022
- 1H01A
- EXP 7/31/2023
- (b) 1E32A
- EXP 4/30/2023
- 1F45A
- EXP 5/31/2023
- 1H99A
- 1K84A
- EXP 9/30/2023
- (c) 0L40A
- EXP 10/31/2022
- 1B38A
- EXP 1/31/2023
- 1E12A
- 1F41A
- 1G73A
- 1G68A
- EXP 6/30/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27